Black patients with triple-negative breast cancer may be less likely to receive immunotherapy than white patients
In recent years, Black patients with triple-negative breast cancer (TNBC) received immunotherapy at significantly lower rates ...
HealthDay on MSN9h
Adjuvant Pembrolizumab Improves Survival in Muscle-Invasive Urothelial Cancer
Disease-free survival is significantly longer with adjuvant pembrolizumab than observation among patients with high-risk ...
pulmonologyadvisor17h
Keytruda Plus Chemotherapy Approved for Malignant Pleural Mesothelioma
The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.
Targeted Oncology20h
GU Oncology Peers Explore Early Therapy Approaches in Low-Volume mRCC
During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on treating patients with indolent or ...
Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced ...
ThePrint22h
This experimental lung cancer drug outperforms blockbuster medicine Keytruda. But there’s a catch
In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.